


IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Currently Amended): A method of treating or preventing at least one disease, in a mammal in need thereof, wherein the at least one disease is selected from the group consisting of diabetes, inadequate glucose tolerance, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, and polycystic ovary syndrome, comprising

administering at least one alkynyl aryl carboxamide of Formula (I')



as well as its geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts thereof, wherein

A is a C<sub>2</sub>-C<sub>15</sub> alkynyl, or C<sub>2</sub>-C<sub>6</sub>-alkynyl aryl, ~~or C<sub>2</sub>-C<sub>6</sub>-alkynyl heteroaryl~~;

Cy is an aryl, ~~heteroaryl~~, ~~a 3-8 membered cycloalkyl or a heterocycle group~~;

Cy' is an aryl, which may optionally be fused by a 3-8 membered cycloalkyl;

n is 0 or 1;

R<sub>1</sub> and R<sub>2</sub> are independently from each other selected from the group consisting of hydrogen and C<sub>1</sub>-C<sub>6</sub>-alkyl;


R<sub>3</sub> is selected from the group consisting of C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, C<sub>1</sub>-C<sub>6</sub>-alkoxy, C<sub>1</sub>-C<sub>6</sub>-alkyl amine, C<sub>1</sub>-C<sub>6</sub>-alkyl alkoxy, C<sub>1</sub>-C<sub>6</sub>-alkyl carboxy, aryl, heteroaryl, saturated or unsaturated 3-8-membered cycloalkyl, 3-8-membered heterocycloalkyl, C<sub>1</sub>-C<sub>6</sub>-alkyl aryl, C<sub>1</sub>-C<sub>6</sub>-alkyl heteroaryl, C<sub>2</sub>-C<sub>6</sub>-alkenyl aryl, C<sub>2</sub>-C<sub>6</sub>-alkenyl heteroaryl, C<sub>2</sub>-C<sub>6</sub>-alkynyl aryl; C<sub>2</sub>-C<sub>6</sub>-alkynyl heteroaryl, C<sub>1</sub>-C<sub>6</sub>-alkyl cycloalkyl, C<sub>1</sub>-C<sub>6</sub>-alkyl heterocycloalkyl,

C<sub>2</sub>-C<sub>6</sub>-alkenyl cycloalkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl heterocycloalkyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl cycloalkyl, and C<sub>2</sub>-C<sub>6</sub>-alkynyl heterocycloalkyl;

R<sup>4</sup> and R<sup>5</sup> are independently from each other selected from the group consisting of H, hydroxy, fluoro, C<sub>1</sub>-C<sub>6</sub> alkyl, carboxy, C<sub>1</sub>-C<sub>6</sub> alkoxy, C<sub>1</sub>-C<sub>3</sub> alkyl carboxy, C<sub>2</sub>-C<sub>3</sub> alkenyl carboxy, and C<sub>2</sub>-C<sub>3</sub> alkynyl carboxy, wherein at least one of R<sup>4</sup> or R<sup>5</sup> is neither a hydrogen nor a C<sub>1</sub>-C<sub>6</sub> alkyl; to the mammal in an amount sufficient to treat or prevent the at least one disease.

Claim 2 (Currently Amended): A method of treating or preventing-at least one disease in a mammal in need thereof, wherein the at least one disease is selected from the group consisting of diabetes, inadequate glucose tolerance, hyperlipidemia, hypertriglyceridemia, hypercholerstrolemia, obesity, and polycystic ovary syndrome, comprising

administering at least one alkynyl aryl carboxamide of Formula (I)



as well as its geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts thereof, wherein

A is a C<sub>2</sub>-C<sub>15</sub> alkynyl, or C<sub>2</sub>-C<sub>6</sub>-alkynyl aryl, ~~or C<sub>2</sub>-C<sub>6</sub>-alkynyl heteroaryl~~;

Cy is an aryl, ~~heteroaryl, a 3-8 membered cycloalkyl or a heterocycle group~~;


n is 0 or 1;

R<sup>1</sup> and R<sup>2</sup> are independently from each other selected from the group consisting of hydrogen and C<sub>1</sub>-C<sub>6</sub>-alkyl;

$R^3$  is selected from the group consisting of  $C_1$ - $C_6$ -alkyl,  $C_2$ - $C_6$ -alkenyl,  $C_2$ - $C_6$ -alkynyl,  $C_1$ - $C_6$ -alkoxy,  $C_1$ - $C_6$ -alkyl amine,  $C_1$ - $C_6$ -alkyl alkoxy, aryl, heteroaryl, saturated 3-8-membered cycloalkyl, unsaturated 3-8 membered cycloalkyl, 3-8-membered heterocycloalkyl, an acyl moiety,  $C_1$ - $C_6$ -alkyl aryl,  $C_1$ - $C_6$ -alkyl heteroaryl,  $C_2$ - $C_6$ -alkenyl aryl,  $C_2$ - $C_6$ -alkenyl heteroaryl,  $C_2$ - $C_6$ -alkynyl aryl,  $C_2$ - $C_6$ -alkynyl heteroaryl,  $C_1$ - $C_6$ -alkyl cycloalkyl,  $C_1$ - $C_6$ -alkyl heterocycloalkyl,  $C_2$ - $C_6$ -alkenyl cycloalkyl,  $C_2$ - $C_6$ -alkenyl heterocycloalkyl,  $C_2$ - $C_6$ -alkynyl cycloalkyl, and  $C_2$ - $C_6$ -alkynyl heterocycloalkyl;

$R^4$  and  $R^5$  are each independently from each other selected from the group consisting of H, hydroxy,  $C_1$ - $C_6$  alkyl, carboxy,  $C_1$ - $C_6$  alkoxy,  $C_1$ - $C_3$  alkyl carboxy,  $C_2$ - $C_3$  alkenyl carboxy,  $C_2$ - $C_3$  alkynyl carboxy, and amino, or  $R^4$  and  $R^5$  may form an unsaturated or saturated heterocyclic ring, wherein at least one of  $R^4$  or  $R^5$  is not a hydrogen or  $C_1$ - $C_6$  alkyl; to the mammal in an amount sufficient to treat or prevent the at least one disease.

Claim 3 (Currently Amended): A method of treating or preventing at least one disease in a mammal in need thereof, wherein the at least one disease is selected from the group consisting of metabolic disorders mediated by insulin resistance or hyperglycemia, inflammatory diseases, and combinations thereof, comprising administering at least one alkynyl aryl carboxamide of Formula (I')



as well as its geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts thereof, wherein

A is a  $C_2$ - $C_{15}$  alkynyl, or  $C_2$ - $C_6$ -alkynyl aryl, ~~or  $C_2$ - $C_6$ -alkynyl heteroaryl;~~

Cy is an aryl, ~~heteroaryl, a 3-8 membered cycloalkyl or a heterocycle group;~~

Cy' is an aryl, which may optionally be fused by a 3-8 membered cycloalkyl;

n is 0 or 1;

R<sub>1</sub> and R<sub>2</sub> are independently from each other selected from the group consisting of hydrogen and C<sub>1</sub>-C<sub>6</sub>-alkyl;

R<sub>3</sub> is selected from the group consisting of C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, C<sub>1</sub>-C<sub>6</sub>-alkoxy, C<sub>1</sub>-C<sub>6</sub>-alkyl amine, C<sub>1</sub>-C<sub>6</sub>-alkyl alkoxy, C<sub>1</sub>-C<sub>6</sub>-alkyl carboxy, aryl, heteroaryl, saturated or unsaturated 3-8-membered cycloalkyl, 3-8-membered heterocycloalkyl, C<sub>1</sub>-C<sub>6</sub>-alkyl aryl, C<sub>1</sub>-C<sub>6</sub>-alkyl heteroaryl, C<sub>2</sub>-C<sub>6</sub>-alkenyl aryl, C<sub>2</sub>-C<sub>6</sub>-alkenyl heteroaryl, C<sub>2</sub>-C<sub>6</sub>-alkynyl aryl; C<sub>2</sub>-C<sub>6</sub>-alkynyl heteroaryl, C<sub>1</sub>-C<sub>6</sub>-alkyl cycloalkyl, C<sub>1</sub>-C<sub>6</sub>-alkyl heterocycloalkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl cycloalkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl heterocycloalkyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl cycloalkyl, and C<sub>2</sub>-C<sub>6</sub>-alkynyl heterocycloalkyl;

R<sup>4</sup> and R<sup>5</sup> are independently from each other selected from the group consisting of H, hydroxy, fluoro, C<sub>1</sub>-C<sub>6</sub> alkyl, carboxy, C<sub>1</sub>-C<sub>6</sub> alkoxy, C<sub>1</sub>-C<sub>3</sub> alkyl carboxy, C<sub>2</sub>-C<sub>3</sub> alkenyl carboxy, and C<sub>2</sub>-C<sub>3</sub> alkynyl carboxy, wherein at least one of R<sup>4</sup> or R<sup>5</sup> is neither a hydrogen nor a C<sub>1</sub>-C<sub>6</sub> alkyl; to the mammal in an amount sufficient to treat or prevent the at least one disease.

Claim 4 (Previously Presented): The method of claim 1, wherein the method is a method of treating.

Claim 5 (Previously Presented): The method of claim 2, wherein the method is a method of treating .

Claim 6 (Previously Presented): The method of claim 3, wherein the method is a method of treating.


Claims 7-8 (Canceled).

Claim 9 (Previously Presented): The method of claim 1, wherein  $R^1$  and  $R^2$  are each H.

Claim 10 (Previously Presented): The method of claim 1, wherein Cy is a phenyl group.

Claim 11 (Previously Presented): The method of claim 1, wherein A is a moiety of the formula  $-C\equiv C-R^6$ , and wherein  $R^6$  is  $C_6$ - $C_{12}$  alkyl, a 3-8 membered cycloalkyl,  $C_1$ - $C_6$  alkyl-(3-8 membered) cycloalkyl,  $C_2$ - $C_6$ -alkenyl,  $C_2$ - $C_6$ -alkynyl, phenyl,  $C_1$ - $C_{12}$  alkyl phenyl,  $C_2$ - $C_6$ -alkenyl phenyl, or a  $C_2$ - $C_6$ -alkynyl phenyl.

Claim 12 (Currently Amended): An alkynyl aryl carboxamide or its salt according to any of formulae (Ia), (Ib), (Ic) or (If):



wherein

A is a  $C_2$ - $C_{15}$  alkynyl, or  $C_2$ - $C_6$ -alkynyl aryl, ~~or  $C_2$ - $C_6$ -alkynyl heteroaryl;~~


Cy is an aryl, ~~heteroaryl, a 3-8 membered cycloalkyl or a heterocycle group;~~

n is 0 or 1;

$R^1$  and  $R^2$  are independently from each other is selected from the group consisting of hydrogen and  $C_1$ - $C_6$ -alkyl; and wherein

$R^3$  is selected from the group consisting of H, hydroxy,  $C_1$ - $C_6$ -alkyl,  $C_2$ - $C_6$ -alkenyl,  $C_2$ - $C_6$ -alkynyl,  $C_1$ - $C_6$ -alkoxy,  $C_1$ - $C_6$ -alkyl amine,  $C_1$ - $C_6$ -alkyl alkoxy, aryl, heteroaryl, saturated or unsaturated 3-8-membered cycloalkyl, 3-8-membered heterocycloalkyl, an acyl moiety,  $C_1$ - $C_6$ -alkyl aryl,  $C_1$ - $C_6$ -alkyl heteroaryl,  $C_2$ - $C_6$ -alkenyl aryl,  $C_2$ - $C_6$ -alkenyl heteroaryl,  $C_2$ - $C_6$ -alkynyl aryl,  $C_2$ - $C_6$ -alkynyl heteroaryl,  $C_1$ - $C_6$ -alkyl cycloalkyl,  $C_1$ - $C_6$ -alkyl heterocycloalkyl,  $C_2$ - $C_6$ -alkenyl cycloalkyl,  $C_2$ - $C_6$ -alkenyl heterocycloalkyl,  $C_2$ - $C_6$ -alkynyl cycloalkyl, and  $C_2$ - $C_6$ -alkynyl heterocycloalkyl.

Claim 13 (Currently Amended): An alkynyl aryl carboxamide or its salt according to claim 12 having the formula (Ib)



wherein

A is a  $C_2$ - $C_{15}$  alkynyl, or  $C_2$ - $C_6$ -alkynyl aryl, ~~or  $C_2$ - $C_6$ -alkynyl heteroaryl;~~

Cy is an aryl, ~~heteroaryl, a 3-8 membered cycloalkyl or a heterocycle group;~~



n is 0 or 1;

$R^1$  and  $R^2$  are independently from each other is selected from the group consisting of hydrogen and  $C_1$ - $C_6$ -alkyl; and wherein

$R^3$  is selected from the group consisting of H, hydroxy,  $C_1$ - $C_6$ -alkyl,  $C_2$ - $C_6$ -alkenyl,  $C_2$ - $C_6$ -alkynyl,  $C_1$ - $C_6$ -alkoxy,  $C_1$ - $C_6$ -alkyl amine,  $C_1$ - $C_6$ -alkyl alkoxy, aryl, heteroaryl, saturated

or unsaturated 3-8-membered cycloalkyl, 3-8-membered heterocycloalkyl, an acyl moiety, C<sub>1</sub>-C<sub>6</sub>-alkyl aryl, C<sub>1</sub>-C<sub>6</sub>-alkyl heteroaryl, C<sub>2</sub>-C<sub>6</sub>-alkenyl aryl, C<sub>2</sub>-C<sub>6</sub>-alkenyl heteroaryl, C<sub>2</sub>-C<sub>6</sub>-alkynyl aryl, C<sub>2</sub>-C<sub>6</sub>-alkynyl heteroaryl, C<sub>1</sub>-C<sub>6</sub>-alkyl cycloalkyl, C<sub>1</sub>-C<sub>6</sub>-alkyl heterocycloalkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl cycloalkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl heterocycloalkyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl cycloalkyl, and C<sub>2</sub>-C<sub>6</sub>-alkynyl heterocycloalkyl.

Claim 14 (Currently Amended): An alkynyl aryl carboxamide or its salt according to any of formulae (Id) or (Ie):



wherein

A is a C<sub>2</sub>-C<sub>15</sub> alkynyl, or C<sub>2</sub>-C<sub>6</sub>-alkynyl aryl, ~~or C<sub>2</sub>-C<sub>6</sub>-alkynyl heteroaryl~~;

Cy is an aryl, ~~heteroaryl, a 3-8 membered cycloalkyl or heterocycle group~~;

n is 0 or 1;

R<sup>1</sup> and R<sup>2</sup> are independently from each other is selected from the group consisting of hydrogen and C<sub>1</sub>-C<sub>6</sub>-alkyl;

R<sup>3</sup> is selected from the group consisting of C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, C<sub>1</sub>-C<sub>6</sub>-alkoxy, C<sub>1</sub>-C<sub>6</sub>-alkyl amine, C<sub>1</sub>-C<sub>6</sub>-alkyl alkoxy, aryl, heteroaryl, saturated 3-8-membered cycloalkyl, unsaturated 3-8 membered cycloalkyl, 3-8-membered heterocycloalkyl, an acyl moiety, C<sub>1</sub>-C<sub>6</sub>-alkyl aryl, C<sub>1</sub>-C<sub>6</sub>-alkyl heteroaryl, C<sub>2</sub>-C<sub>6</sub>-alkenyl aryl, C<sub>2</sub>-C<sub>6</sub>-alkenyl heteroaryl, C<sub>2</sub>-C<sub>6</sub>-alkynyl aryl, C<sub>2</sub>-C<sub>6</sub>-alkynyl heteroaryl, C<sub>1</sub>-C<sub>6</sub>-alkyl cycloalkyl, C<sub>1</sub>-C<sub>6</sub>-alkyl heterocycloalkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl cycloalkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl heterocycloalkyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl cycloalkyl, and C<sub>2</sub>-C<sub>6</sub>-alkynyl heterocycloalkyl.

Claim 15 (Previously Presented): The alkynyl aryl carboxamide or its salt of claim 12, wherein R<sup>1</sup> and R<sup>2</sup> are each H, Cy is a phenyl group, and A is a moiety of the formula -C≡C-R<sup>6</sup>; wherein R<sup>6</sup> is C<sub>6</sub>-C<sub>12</sub> alkyl, a 3-8 membered cycloalkyl, C<sub>1</sub>-C<sub>6</sub> alkyl-(3-8 membered) cycloalkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, phenyl, C<sub>1</sub>-C<sub>12</sub> alkyl phenyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl phenyl, or C<sub>2</sub>-C<sub>6</sub>-alkynyl phenyl.

Claim 16 (Currently Amended): The alkynyl aryl carboxamide or its salt claim 12, selected from the group consisting of:

- 5-[(3-Cyclopentylpropanoyl)(4-dec-1-ynylbenzyl)amino]-2-hydroxybenzoic acid;
- 5-[(3-Cyclopentylpropanoyl)(4-dec-1-ynylbenzyl)amino]-2-hydroxybenzoic acid, N-methyl-D-glucamine;
- 5-[ {4-[(4-Butylphenyl)ethynyl]benzyl} (3-cyclopentylpropanoyl)amino]-2-hydroxybenzoic acid;
- 5-[(4-[(4-Butylphenyl)ethynyl]benzyl) (3-cyclopentylpropanoyl)amino]-2-hydroxybenzoic acid, N-methyl-D-glucamine;
- 5-[Acetyl(4-dec-1-ynylbenzyl)amino]-2-hydroxybenzoic acid;
- 5-[(4-Dec-1-ynylbenzyl)(pyridin-3-ylcarbonyl)amino]-2-hydroxybenzoic acid;
- 5-[(4-Dec-1-ynylbenzyl)(isonicotinoyl)amino]-2-hydroxybenzoic acid;
- 5-((4-Dec-1-ynylbenzyl)[(2E)-3-phenylprop-2-enoyl]amino)-2-hydroxybenzoic acid;
- 5-[(4-Dec-1-ynylbenzyl)(thien-2-ylacetyl)amino]-2-hydroxybenzoic acid;
- 5-((4-Dec-1-ynylbenzyl) { (2E)-3-[3-(trifluoromethyl)phenyl]prop-2-enoyl } amino)-2-hydroxybenzoic acid;
- 5-[(4-Dec-1-ynylbenzyl)(phenoxyacetyl)amino]-2-hydroxybenzoic acid;



[4-((4-Dec-1-ynylbenzyl)[(2E)-3-phenylprop-2-enoyl]amino)methyl]phenoxy]acetic acid;

(4-{ [(3-Cyclopentylpropanoyl)(4-dec-1-ynylbenzyl)amino]methyl }phenoxy)acetic acid;

(4-{[(4-Dec-1-ynylbenzyl)(hexanoyl)amino]methyl}phenoxy)acetic acid;

(4-{[Acetyl(4-dec-1-ynylbenzyl)amino]methyl}phenoxy)acetic acid;

2-(Carboxymethoxy)-5-({ (4-dec-1-ynylbenzyl) [(2E)-3-phenylprop-2-enoyl]amino)methyl)benzoic acid;

2-(Carboxymethoxy)-5-{ [(3-cyclopentylpropanoyl)(4-dec-1-ynylbenzyl)amino]methyl}benzoic acid;

5-{[Acetyl(4-dec-1-ynylbenzyl)amino]methyl}-2-(carboxymethoxy)benzoic acid  
(2E)-3-(4-{ [(4-Dec-1-ynylbenzyl)(3-phenylpropanoyl)amino]methyl}phenyl)acrylic acid;

(2E)-3-(4-[(4-Dec-1-ynylbenzyl)(3-phenylpropanoyl)amino]phenyl} acrylic acid ;

(2E)-3-{4-[Acetyl(4-dec-1-ynylbenzyl)amino]phenyl} acrylic acid;

3-(4-{ [(3-Cyclopentylpropanoyl)(4-dec-ynylbenzyl)amino]methyl}phenyl)propanoic acid;

5-[ {4-[(4-Butylphenyl)ethynyl]benzyl}(cyclohexylcarbonyl)amino]-2-hydroxybenzoic acid;

5-[ {4-[(4-Butylphenyl)ethynyl]benzyl}(hexanoyl)amino]-2-hydroxybenzoic acid, N-methyl-D-glucamine;

5-((4-tert-Butylbenzoyl) { 4-[(4-butylphenyl)ethynyl]benzyl } amino)-2-hydroxybenzoic acid, N-methyl-D-glucamine;

5-((Biphenyl-4-ylcarbonyl) { 4-[(4-butylphenyl)ethynyl]benzyl } amino)-2-hydroxybenzoic acid;

5-[ {4-[(4-Butylphenyl)ethynyl]benzyl} (3,3-dimethylbutanoyl)amino]-2-hydroxybenzoic acid;

5-[ {4-[(4-Butylphenyl)ethynyl]benzyl} (2,3-dihydro-1-benzofuran-5-ylcarbonyl)amino]-2-hydroxybenzoic acid;

5-[ { 4-[(4-Butylphenyl)ethynyl]benzyl} (7-carboxyheptanoyl)amino]-2-hydroxybenzoic acid;

5-((1,3-Benzodioxol-5-ylcarbonyl) {4-[(4-butylphenyl)ethynyl]benzyl} amino)-2-hydroxybenzoic acid;

5-[ {4-[(4-Butylphenyl)ethynyl]benzyl} (2,2-dimethylpropanoyl)amino]-2-hydroxybenzoic acid;

5-([(Benzyloxy)acetyl] {4-[(4-butylphenyl)ethynyl]benzyl } amino)-2-hydroxybenzoic acid;

5-[ {4-[(4-Butylphenyl)ethynyl]benzyl} (4-hexylbenzoyl)amino]-2-hydroxybenzoic acid;

5-[ {4-[(4-Butylphenyl)ethynyl]benzyl} (2-naphthoyl)amino]-2-hydroxybenzoic acid;

5-((1-Benzothien-2-ylcarbonyl) {4-[(4-butylphenyl)ethynyl]benzyl} amino)-2-hydroxybenzoic acid, N-methyl-D-glucamine;

4-[ {4-[(4-Butylphenyl)ethynyl]benzyl} (3-cyclopentylpropanoyl)amino]-2-hydroxybenzoic acid, N-methyl-D-glucamine;

5- { [ {4-[(4-Butylphenyl)ethynyl]benzyl } (3-cyclopentylpropanoyl)amino]methyl} -2-hydroxybenzoic acid, N-methyl-D-glucamine;

5- { [ {4-[(4-Butylphenyl)ethynyl]benzyl } (hexanoyl)amino]methyl} -2-hydroxybenzoic acid;

(4- { [ {4-[(4-Butylphenyl)ethynyl]benzyl} (hexanoyl)amino]methyl} phenoxy)acetic acid, N-methyl-D-glucamine;

(4- { [ {4-[(4-Butylphenyl)ethynyl]benzyl } (cyanoacetyl)amino]methyl  
phenoxy)acetic acid;

(4- { [ {4-[(4-Butylphenyl)ethynyl]benzyl) (1 H-indazol-3-ylcarbonyl)amino]methyl)-  
phenoxy)acetic acid;

(4- { [ {4-[(4-Butylphenyl)ethynyl]benzyl) (pent-4-ynoyl)amino]methyl}phenoxy)-  
acetic acid;

[4-({4-[(4-Butylphenyl)ethynyl]benzyl} [(6-hydroxypyridin-3-yl)carbonyl]amino)-  
methyl-phenoxy]acetic acid;

[4-({ {4-[(4-Butylphenyl)ethynyl]benzyl} [(2-methoxyethoxy)acetyl]amino }methyl)-  
phenoxy]acetic acid;

(4- { [ {4-[(4-Butylphenyl)ethynyl]benzyl) (1 H-pyrazol-4-ylcarbonyl)amino]-  
methyl)phenoxy)acetic acid 3-[(3-Cyclopentylpropanoyl)(4-dec-1-yn-1-  
ylbenzyl)amino]benzoic acid, N-methyl-D-glucamine;

3-[(4-Dec-1-yn-1-ylbenzyl)(hexanoyl)amino]benzoic acid;

4- { [ {4-[(4-Butylphenyl)ethynyl]benzyl } (3-cyclopentylpropanoyl)amino]methyl )-  
benzoic acid;

4- {[ {4-[(4-Butylphenyl)ethynyl]benzyl)(hexanoyl)amino]methyl} benzoic acid;

4-[[{(4-tert-Butylbenzoyl) { 4-[(4-butylphenyl)ethynyl]benzyl } amino)methyl]benzoic  
acid;

4-[ {4-[(4-Butylphenyl)ethynyl]benzyl)(hexanoyl)amino]benzoic acid;

4-[ {4-[(4-Butylphenyl)ethynyl]benzyl)(3-cyclopentylpropanoyl)amino]benzoic acid; \

8-[ {4-[(4-Butylphenyl)ethynyl]benzyl)(3-cyclopentylpropanoyl)amino]-5,6,7,8-  
tetrahydronaphthalene-2-carboxylic acid, N-methyl-D-glucamine;

5-[ {4-[(4-Chlorophenyl)ethynyl]benzyl}(3-cyclopentylpropanoyl)amino]-2-  
hydroxybenzoic acid, N-methyl-D-glucamine;

5-[f 4-[(4-Chlorophenyl)ethynyl]benzyl } (4-heptylbenzoyl)amino]-2-hydroxybenzoic acid;

5-[ {4-[(4-Chlorophenyl)ethynyl]benzyl } (isoxazol-5-ylcarbonyl)amino]-2-hydroxybenzoic acid;

5-[ {4-[(4-Chlorophenyl)ethynyl]benzyl } (2-thienylacetyl)amino]-2-hydroxybenzoic acid;

5-[ {4-[(4-Chlorophenyl)ethynyl]benzyl } (3-phenylpropanoyl)amino]-2-hydroxybenzoic acid, N-methyl-D-glucamine;

5-[ {4-[(4-Chlorophenyl)ethynyl]benzyl } (4-methoxybenzoyl)amino]-2-hydroxybenzoic acid, N-methyl-D-glucamine ;

5-[ {4-[(4-Chlorophenyl)ethynyl]benzyl } (3-fluorobenzoyl)amino]-2-hydroxybenzoic acid, N-methyl-D-glucamine;

5-[ {4-[(4-Chlorophenyl)ethynyl]benzyl } (cyclohexylcarbonyl)amino]-2-hydroxybenzoic acid, N-methyl-D-glucamine ;

5-(acetyl {4-[(4-Chlorophenyl)ethynyl]benzyl } amino)-2-hydroxybenzoic acid, N-methyl-D-glucamine;

5-[ {4-[(4-Butylphenyl)ethynyl]-2-fluorobenzyl } (3-cyclopentylpropanoyl)amino]-2-hydroxybenzoic acid, N-methyl-D-glucamine;

8-((3-Cyclopentylpropanoyl) {4-[(4-fluorophenyl)ethynyl]benzyl } amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid, N-methyl-D-glucamine;

~~5-[({6-[(4-Butylphenyl)ethynyl]pyridin-3-yl}methyl)(3-cyclopentylpropanoyl)-amino]-2-hydroxybenzoic acid, N-methyl-D-glucamine~~

5-[f 4-[(4-Butylphenyl)ethynyl]benzyl } (3-cyclopentylpropanoyl)amino]-2-fluorobenzoic acid, N-methyl-D-glucamine ;

5-[ {4-[(4-Butylphenyl)ethynyl]benzyl)(3,3-dimethylbutanoyl)amino]-2-fluorobenzoic acid, N-methyl-D-glucamine ;

5-[ {4-[(4-Butylphenyl)ethynyl]benzyl)(2-thienylacetyl)amino]-2-fluorobenzoic acid, N-methyl-D-glucamine;

4-[ {4-[(4-Butylphenyl)ethynyl]benzyl) (3,3-dimethylbutanoyl)amino]-2-hydroxybenzoic acid, N-methyl-D-glucamine;

3-[ {4-[(4-Butylphenyl)ethynyl]benzyl)(3-cyclopentylpropanoyl)amino]-4-fluorobenzoic acid;

4-[ {4-[(4-Chlorophenyl)ethynyl]benzyl} (3-cyclopentylpropanoyl)amino]-2-hydroxybenzoic acid, N-methyl-D-glucamine;

4-(Acetyl {4-[(4-butylphenyl)ethynyl]benzyl} amino)-2-hydroxybenzoic acid, N-methyl-D-glucamine;

4-[ {4-[(4-Butylphenyl)ethynyl]benzyl } (cyclohexylcarbonyl)amino]-2-hydroxybenzoic acid, N-methyl-D-glucamine;

4-[ {4-[(4-Butylphenyl)ethynyl]benzyl)(hexanoyl)amino]-2-hydroxybenzoic acid, N-methyl-D-glucamine;

4-[ {4-[(4-Butylphenyl)ethynyl]benzyl)(3-cyclopentylpropanoyl)amino]-2-fluorobenzoic acid, N-methyl-D-glucamine;

4-[ {4-[(4-Butylphenyl)ethynyl]benzyl) (2,2-dimethylpropanoyl)amino]-2-hydroxybenzoic acid, N-methyl-D-glucamine;

4-((3-Cyclopentylpropanoyl) (4-[(4-methoxyphenyl)ethynyl]benzyl} amino)-2-hydroxybenzoic acid, N-methyl-D-glucamine;

4-[ {4-[(4-tert-Butylphenyl)ethynyl]benzyl} (3-cyclopentylpropanoyl)amino]-2-hydroxybenzoic acid, N-methyl-D-glucamine;

4-((3-Cyclopentylpropanoyl) {4-[(4-propoxyphenyl)ethynyl]benzyl } amino)-2-hydroxybenzoic acid, N-methyl-D-glucamine;

4-((3-Cyclopentylpropanoyl){4-[(4-propylphenyl)ethynyl]benzyl} amino)-2-hydroxybenzoic acid, N-methyl-D-glucamine, and

4-{(3-Cyclopentylpropanoyl)[4-(5-phenylpent-1-yn-1-yl)benzyl]amino)-2-hydroxybenzoic acid, N-methyl-D-glucamine.

Claim 17 (Previously Presented): A composition comprising at least one alkynyl aryl carboxamide of claim 12 or its salt and a pharmaceutically acceptable carrier, diluent, excipient, or combination thereof.


Claim 18 (Previously Presented): A pharmaceutical composition comprising at least one alkynyl aryl carboxamide of claim 13 or its salt and a pharmaceutically acceptable carrier, diluent excipient, or combination thereof.

Claim 19 (Previously Presented): The pharmaceutical composition of claim 18, further comprising at least one supplementary drug selected from the group consisting of insulin, aldose reductase inhibitors, alpha-glucosidase inhibitors, sulfonyl urea agents, biguanides thiazolidindiones, PPARs agonists, c-Jun Kinase and GSK-3 inhibitors.

Claim 20 (Previously Presented): The pharmaceutical composition of claim 19 wherein the at least one supplementary drug is selected from the group consisting of a rapid acting insulin, an intermediate acting insulin, a long acting insulin, a combination of intermediate and rapid acting insulins, Minalrestat, Tolrestat, Sorbinil, Methosorbinil, Zopolrestat, Epalrestat, Zenarestat, Imirestat, Ponalrestat, ONO-2235, GP-1447, CT-112, BAL-ARI 8,

Miglitol, Acarbose, Glipizide, Glyburide, Chlorpropamide, Tolbutamide, Tolazamide, [[or]] and Glimepiride.

Claim 21 (Previously Presented): A method of preparing the alkynyl aryl carboxamide of claim 12, comprising deprotecting, transforming, or deprotecting and transforming the compound of formula (Z) to form the alkynyl aryl carboxamide of formula (I)



wherein FG is A or a leaving group.

Claims 22-24 (Canceled).

Claim 25 (Previously Presented): The method of claim 2, wherein R<sup>1</sup> and R<sup>2</sup> are each H.

Claim 26 (Previously Presented): The method of claim 3, wherein R<sup>1</sup> and R<sup>2</sup> are each H.

Claim 27 (Previously Presented): The method of claim 2, wherein Cy is a phenyl group.

Claim 28 (Previously Presented): The method of claim 3, wherein Cy is a phenyl group.

Claim 29 (Previously Presented): The method of claim 2, wherein A is a moiety of the formula  $-C \equiv C-R^6$ , and wherein  $R^6$  is  $C_6-C_{12}$  alkyl, a 3-8 membered cycloalkyl,  $C_1-C_6$  alkyl-(3-8 membered) cycloalkyl,  $C_2-C_6$ -alkenyl,  $C_2-C_6$ -alkynyl, phenyl,  $C_1-C_{12}$  alkyl phenyl,  $C_2-C_6$ -alkenyl phenyl, or a  $C_2-C_6$ -alkynyl phenyl.

Claim 30 (Previously Presented): The method of claim 3, wherein A is a moiety of the formula  $-C \equiv C-R^6$ , and wherein  $R^6$  is  $C_6-C_{12}$  alkyl, a 3-8 membered cycloalkyl,  $C_1-C_6$  alkyl-(3-8 membered) cycloalkyl,  $C_2-C_6$ -alkenyl,  $C_2-C_6$ -alkynyl, phenyl,  $C_1-C_{12}$  alkyl phenyl,  $C_2-C_6$ -alkenyl phenyl, or a  $C_2-C_6$ -alkynyl phenyl.